A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain

The level of the endocannabinoid anandamide is controlled by fatty acid amide hydrolase (FAAH). In 2011, PF-04457845, an irreversible inhibitor of FAAH, was progressed to phase II clinical trials for osteoarthritic pain. This article discusses a prospective, integrated systems pharmacology model eva...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Benson, N, Metelkin, E, Demin, O, Li, G L, Nichols, D, van der Graaf, P H
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3910012/
https://ncbi.nlm.nih.gov/pubmed/24429592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2013.72
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars